SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following its earnings release, with community chatter focused on the company's role in the AI boom and whether its valuation is justified. Some traders are betting on a continued rally, while others believe it's a pump-and-dump scheme waiting to crash, with several drawing comparisons to historical market bubbles. CEO Jensen Huang's comments on AI and the company's financial strength are also being closely scrutinized.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid anticipation for NVDA's earnings report, viewed as a key indicator for the broader tech sector and AI's continued growth. Community discussions revolve around whether NVDA can maintain bullish momentum or if a "sell the news" event will occur, impacting the overall market. Traders are also reacting to cancelled jobs data and mixed signals regarding potential interest rate cuts.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms (META) is trending as investors grapple with contrasting signals, particularly a perceived "illegal wall" around the $600 price level and discussions about Meta's AI investments following NVDA's earnings call. Community sentiment is mixed, with some hopeful for a breakout and others expressing concern over Meta's spending and its impact on the stock's performance. The debate centers on whether Meta can break through resistance and capitalize on AI opportunities, or if it will continue to face downward pressure due to its financial strategy.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders anticipate a market reaction to key earnings news. Community discussions focus on whether a single stock can sustain the broader market and if AI hype is justified, while others await upcoming economic data for further direction. Overall, the debate centers around the strength and longevity of the current market rally.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as traders debate whether recent price action represents a buying opportunity or a continuation of a downtrend, with some anticipating a potential surge fueled by positive tech earnings. Community discussions revolve around institutional adoption, potential market manipulation, and comparisons to traditional assets like gold. Concerns persist around regulatory headwinds, dormant wallets, and the broader macroeconomic climate.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors anticipate potential benefits from the AI infrastructure boom and an upcoming earnings report from NVDA. Community members are actively discussing price predictions, potential shout-outs from NVDA, and the possibility of a short squeeze. Talk of index inclusion and Saudi investment further fuel interest in NBIS.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending amid discussion of its relationship with NVDA and the broader AI sector, with community members weighing in on whether recent price movements signal a buying opportunity or a continued downturn. Debate centers on the company's debt, growth potential, and sensitivity to overall market sentiment, with some traders expressing bullish sentiment based on the anticipation of further AI sector growth. The stock's recent volatility has sparked discussion about technical analysis, market manipulation, and the influence of key figures like Michael Burry.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

SPDR Dow Jones Industrial Average ETF ($DIA) is trending as markets react to potential government shutdown resolutions. Community members are anticipating a lift as the Senate moves towards a vote, while others remain cautious, citing concerns about the quality of economic data and lingering overbought conditions. Traders are also discussing the potential impact of key economic data releases and earnings reports from major consumer names.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as traders assess its correlation to Ethereum and react to recent price drops. Community members are debating whether it's a buying opportunity or a sign of further decline, with some expressing frustration with the stock's performance and the company's strategy. The upcoming earnings report and potential staking announcements are focal points for future price movement.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors debate the impact of the CEO's recent cautious commentary at a Citi conference and its effect on near-term growth prospects. Community sentiment is mixed, with some seeing a buying opportunity due to the company's fundamentals and buyback program, while others express concern over the stock's continued underperformance compared to competitors like Block ($XYZ).

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review.</li><li>The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” &nbsp;</li></ul>Sensei Biotherapeutics, Inc. (SNSE) on Thursday said that its Board of Directors has determined to discontinue development of its lead product candidate, Solnerstotug, and initiate a comprehensive review of strategic alternatives.The Board came to the decision after extensive consideration, it said. The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/30/3177470/0/en/Sensei-Biotherapeutics-Announces-Initiation-of-Strategic-Review-to-Maximize-Shareholder-Value.html">said</a>. Further, there is no assurance that the review will result in a transaction, the company added.<h2 class="st-heading-2">Workforce Reduction Plans</h2>The company stated that it anticipates reducing its workforce to conserve cash as part of its strategic review. Details of the layoffs will be announced separately, the company said.Sensei Biotherapeutics, however, plans to retain a small team of employees to assist in the strategic review process and to manage a smooth transition of developmental activities. &nbsp;The company said that it decided not to initiate a new clinical study of Solnerstotug in cancer patients after reviewing “future funding needs and current capital markets environment.” The drug had demonstrated clinical activity in previous trials.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company rallied 5% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.SNSE stock is up 5% this year and down by 10% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, Sensei said.

Equity

The company is exploring a range of strategic alternatives that may include, among other options, a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations, Sensei said.


Sensei Biotherapeutics: Peer-reviewed research paper on SNS-101 published

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...

Sensei Biotherapeutics reports FY results

Sensei Biotherapeutics reports FY results...

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade...

Sensei Biotherapeutics (NASDAQ:SNSE)  Shares Down 3.1%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE  Get Free Report)s stock price dropped 3.1% during mid-day trading on Tuesday . The stock traded as low as $0.79 and last traded at $0.79...

Sensei Biotherapeutics to Present at Upcoming Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...

Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 3.8%

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE  Get Free Report) dropped 3.8% during mid-day trading on Monday . The stock traded as low as $0.76 and last traded at $0.76. Approximately...

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Current Price	$9.45
Prev Close	$8.54
Open	$8.15
Dividend Yield	0.00%
50-Day Moving Average	$9.93
Beta	0.80
Avg. Volume	69,816.57
PE Ratio	-0.40

52-Week High	$18.35
52-Week Low	$5.00
Market Capitalization	$10.77M
EPS (Annual)	-$24.01
Price to Book	0.39
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SNSE
Sensei Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNSE News

SNSESensei Biotherapeutics Inc